Literature DB >> 10369084

Analyzing prognostic factors in breast cancer using a multistate model.

P Broët1, A de la Rochefordière, S M Scholl, A Fourquet, Y De Rycke, P Pouillart, V Mosseri, B Asselain.   

Abstract

In breast cancer clinical research, an important goal is to analyze how factors are seen to affect the disease process. Meanwhile, the disease progression is not fully modelled using standard analysis since transitions between intermediate events such as local-regional recurrences (LRR) or metachronous contralateral breast cancer (MCBC) are not considered. In the present study, the progression of disease was modelled using a multistate model. By this approach, we assessed transitions during the course of the disease and studied prognostic factors for each transition. The model was applied to 6,185 patients with unilateral ductal invasive breast cancer, clinical stage I through III, treated between 1981 and 1988 at the Curie Institute. At first diagnosis, high clinical stage, high histological grade, positive lymph nodes, and age less than 40 years were associated with increased risks of LRR, metastases, or death. Except age, the same factors remained predictive for metastases or death following LRR. Chemotherapy for the first cancer was associated with a decreased risk for developing MCBC. As the time interval from diagnosis of the primary tumor to that of a local or contralateral recurrence increased, the risk of metastases or death decreased. Nodal status for the first tumor and clinical stage for the contralateral tumor increased the risk of metastases or death following MCBC. Conversely, the risk decreased for patients who received adjuvant hormone therapy following MCBC. In conclusion, the multistate model offers us a much more appropriate way to study prognostic factors for each transition in breast cancer disease.

Entities:  

Mesh:

Year:  1999        PMID: 10369084     DOI: 10.1023/a:1006197524405

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

2.  Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death.

Authors:  Virginie Rondeau; Simone Mathoulin-Pélissier; Lucie Tanneau; Annie J Sasco; Gaétan Macgrogan; Marc Debled
Journal:  BMC Cancer       Date:  2010-12-31       Impact factor: 4.430

3.  Assessing Prognostic Factors in Hodgkin's Lymphoma: Multistate Illness-Death Model.

Authors:  Fatemeh Javanmardi; Amal Saki-Malehi; Ahmad Ahmadzadeh; Fakher Rahim
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-01-01

4.  Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Authors:  Oscar M Rueda; Stephen-John Sammut; Jose A Seoane; Suet-Feung Chin; Jennifer L Caswell-Jin; Maurizio Callari; Rajbir Batra; Bernard Pereira; Alejandra Bruna; H Raza Ali; Elena Provenzano; Bin Liu; Michelle Parisien; Cheryl Gillett; Steven McKinney; Andrew R Green; Leigh Murphy; Arnie Purushotham; Ian O Ellis; Paul D Pharoah; Cristina Rueda; Samuel Aparicio; Carlos Caldas; Christina Curtis
Journal:  Nature       Date:  2019-03-13       Impact factor: 49.962

5.  Multi-state model for studying an intermediate event using time-dependent covariates: application to breast cancer.

Authors:  Carolina Meier-Hirmer; Martin Schumacher
Journal:  BMC Med Res Methodol       Date:  2013-06-20       Impact factor: 4.615

6.  Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models.

Authors:  Lauren J Beesley; Todd M Morgan; Daniel E Spratt; Udit Singhal; Felix Y Feng; Allison Cullen Furgal; William C Jackson; Stephanie Daignault; Jeremy M G Taylor
Journal:  JAMA Netw Open       Date:  2019-02-01

7.  Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.

Authors:  Sreenath M Krishnan; Lena E Friberg; René Bruno; Ulrich Beyer; Jin Y Jin; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.